CagriSema: Clinical trials, mechanism and approval status
CagriSema: Clinical trials, mechanism and approval status
Evidence-based information about investigational CagriSema, combining cagrilintide and semaglutide.
Overview
CagriSema is an investigational fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. It is being studied for obesity and metabolic disease but is not FDA-approved as a combination product.
Key points
Mechanism
Amylin and GLP-1 pathways may complement appetite and satiety effects.
Evidence
Trial results should be interpreted from peer-reviewed reports and current regulatory documents.
Safety
Tolerability, titration, contraindications and long-term outcomes remain subjects of development.
Legal status
FDA states cagrilintide cannot be used in compounding under federal law and has not been found safe and effective for any condition.
How W8MD can help
W8MD can discuss currently FDA-approved medications and explain how investigational pipeline products differ from lawful prescribed treatment. W8MD does not prescribe or sell compounded cagrilintide or CagriSema.
Frequently asked questions
Is CagriSema approved?
No.
Is it the same as semaglutide?
No. It combines investigational cagrilintide with semaglutide.
Can a pharmacy compound it?
FDA states cagrilintide cannot be used in compounding under federal law.
Evidence and authoritative sources
Contact W8MD
W8MD Weight Loss, Sleep & MedSpa provides physician-supervised care in Brooklyn, New York and Northeast Philadelphia. Telehealth may be available for eligible patients based on location and applicable requirements.
Contact W8MD
